Observational Cohort Study on Adult Patients with Not-adequately Controlled FOcal-onset Seizures Treated with Cenobamate As Early AdjUnctive Therapy in a Real-world Setting - FOCUS

Aim of the study is to better characterize the clinical profile of adjunctive cenobamate by collecting data from the current standard clinical practice in France, Germany, and Spain, to describe the real-world clinical response among adult patients affected by focal epilepsy not adequately controlled despite a history of 2 or 3 ASMs before starting treatment with cenobamate (including previous and concomitant ASMs).

开始日期2024-12-01

申办/合作机构

Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA

[+1]

NCT06453213

/ Recruiting临床4期

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.

开始日期2024-10-14

申办/合作机构

SK Life Science, Inc.

NCT06352723

/ Not yet recruiting早期临床1期IIT

Use of Cenobamate in the Intensive Care Unit for Acute Frequent Seizures and Status Epilepticus

The CENOBITE study will be conducted as a multi-center trial involving X leading centers from the Critical Care EEG Monitoring Consortium (CCEMRC). A total of 10 patients will be recruited over a period of one year, with each patient undergoing monitored treatment regimen. Each site will obtain its own approval from their institutional review board. Data will be shared through the MGB REDCap; raw EEG files will be shared through the MGB Dropbox and analyzed at the BWH.
Monitoring for the development of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, a potential adverse reaction, will be a key aspect of the study. Regular assessments, including RegiSCAR scoring (a validated scoring system for DREeSS5), daily serum cenobamate level measurements, and comprehensive lab tests, will be conducted to ensure patient safety and the effective management of any adverse reactions such as DRESS syndrome.

开始日期2024-04-01

申办/合作机构

The Brigham & Women's Hospital, Inc.

100 项与 Cenobamate 相关的临床结果

登录后查看更多信息

100 项与 Cenobamate 相关的转化医学

登录后查看更多信息

100 项与 Cenobamate 相关的专利（医药）

登录后查看更多信息

230

项与 Cenobamate 相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Budget impact analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands

Article

作者: Rijkers, Kim ; Gubler, Felix ; Hiligsmann, Mickaël ; Laskier-Owens, Vicki ; Evers, Silvia ; Klarenbeek, Pim ; Li, Nannan ; Rouhl, Rob ; Majoie, Marian ; Lazeron, Richard

OBJECTIVE:

The objective of this study was to explore the financial consequences of adopting cenobamate as a treatment alternative in epilepsy patients with drug-resistant focal onset seizures (FOS) from a societal perspective in the Netherlands.

METHODS:

A previous budget impact model with a 5-year time horizon was adapted to the Dutch setting accounting for the eligible population, real-world market shares, treatment effectiveness and resource use in two scenarios: cenobamate with constant market share versus cenobamate with linearly increased market share up to 20%. Clinical inputs included treatment response, seizure reduction and adverse events. Costs consisted of drugs, medical and non-medical costs. One-way sensitivity analysis and scenario analysis were conducted to test the robustness of our results.

RESULTS:

14,723 patients were eligible for cenobamate in 2022. Although cenobamate adds a gross budget impact of €12,686,30, the displacement of other drugs yields a total impact on the drug budget of €3,722,596 over 5 years. Adopting cenobamate resulted in a medical cost savings of €13,499,498 due to less resource use, and non-medical cost savings of €22,144,054 due to reduced productivity losses. Overall, savings generated at medical and non-medical cost level offset the gross drug budget impact of cenobamate, resulting in a saving of €31,920,955 over 5 years. Results were robust in the sensitivity/scenario analyses.

CONCLUSION:

Treatment with cenobamate is associated with both medical and non-medical cost savings, which offset the increase in drug budget and result in a significant potential budget saving. The higher the market share of cenobamate, the larger the budget savings. We acknowledge several limitations; Complex scenarios such as drug interactions, stopping/switching drugs, and multiple drug use were not taken into account. The long-term efficacy and safety of cenobamate and its comparators remains uncertain. Future real-world data are needed to confirm our findings.

2025-04-01·SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Sodium channel blockers for the treatment of focal epilepsy: A Chinese expert consensus

Review

作者: Zhou, Jian ; Liao, Weiping ; Yan, Raowei ; Wu, Xintong ; Zhu, Guoxing ; Wang, Xiaoshan ; Ding, Meiping ; Wang, Yuping ; Liang, Shuli ; Xiao, Bo ; Zhang, Kai ; Zhou, Dong ; Zhu, Suiqiang ; Wang, Tiancheng ; Lin, Weihong ; Liu, Xiaorong ; Zhou, Shuizhen ; Liu, Xuewu ; Zhou, Liemin ; Wang, Xin ; Wang, Xiangqing ; Yu, Peimin ; Hong, Zhen ; Han, Xiong ; Deng, Yanchun ; Wang, Xuefeng ; Zhang, Hesheng

PURPOSE:

To provide consensus-based recommendations for the use of sodium channel blockers (SCBs) in the management of focal epilepsy.

METHODS:

A three-round modified Delphi procedure was conducted among a Delphi panel of 24 Chinese experts to build a consensus. A steering committee developed 9 statements related to SCBs for the treatment of focal epilepsy, and these statements were evaluated and voted upon by the expert panel.

RESULTS:

The expert panel achieved consensus on nine statements regarding the treatment recommendations for oxcarbazepine, lamotrigine, lacosamide, eslicarbazepine, topiramate, zonisamide and cenobamate in focal epilepsy patients and treatment adjustments for SCBs.

CONCLUSION:

This is a Chinese expert consensus on the use of SCBs in focal epilepsy developed using the modified Delphi method. These recommendations can help clinicians in their practice and guide future research.

2025-04-01·EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Adjunctive treatment for pediatric focal epilepsy: a systematic review

Review

作者: Zhang, Xiaolu ; Wang, Zhaoxuan ; Wang, Siru ; Sun, Hu ; Sun, Chunxiao ; Liu, Chang

PURPOSE:

We aim to use a network meta-analysis to evaluate the efficacy and safety of antiseizure medications and provide a theoretical basis for rational drug use for children and adolescents in adjunctive treatment.

METHODS:

The databases of PubMed, Embase, Cochrane Library, and Web of Science were systematically searched for random clinical trials about perampanel, valproic acid, carbamazepine, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, topiramate, zonisamide, brivaracetam, cenobamate, eslicarbazepine acetate, and pregabalin from their inception until December 10, 2023. The included studies' risk of bias was evaluated by the Cochrane Collaboration's tool (RoB2). The network meta-analysis was performed using Stata 15 on the included studies.

RESULTS:

Seventeen studies were identified and of these 19 randomized controlled trials evaluating 9 different antiepileptic drugs were included. In total, 2959 patients were covered in the analysis of the outcomes. For efficacy, lacosamide (OR = 1.91, 95%CI 1.14-3.20), lamotrigine (OR = 3.82, 95%CI 1.86-7.83), levetiracetam (OR = 3.01, 95%CI 1.89-4.80), oxcarbazepine (OR = 2.75, 95%CI 1.52-4.96), perampanel (OR = 2.05, 95%CI 1.15-3.65), and zonisamide (OR = 2.27, 95%CI 1.21-4.24) were more effective than placebo in the 50% responder rate. Lamotrigine ranked first on the cumulative probability curve, followed by levetiracetam. Eslicarbazepine acetate (OR = 6.44, 95%CI 1.43-29.00) and levetiracetam (OR = 5.75, 95%CI 2.45-13.50) were better than placebo in seizure freedom. For safety, topiramate (OR = 4.11, 95%CI 1.43-11.76) and oxcarbazepine (OR = 2.72, 1.28-5.76) were more likely to cause adverse effects in children or adolescents compared to placebo.

CONCLUSION:

In terms of efficacy and safety, lamotrigine and levetiracetam may be selected preferentially for the adjunctive treatment of focal epilepsy in children and adolescents. However, owing to the limited random clinical trials, our results need to be verified by further studies.

项与 Cenobamate 相关的新闻（医药）

2025-03-28

·医脉通

《新生儿肠外营养管理专家共识（2025）》发布！近期更新重点指南一览~

经常错过自己最关注的指南上新内容？想要及时接收到指南上新提醒？临床指南APP——微信绑定功能即可满足~TIPS：首次完成绑定还可得3天临床指南VIP！>具体方法本周热门指南推荐直接点击即可阅读新生儿肠外营养管理专家共识（2025）肠外营养（parenteral nutrition, PN）已广泛应用于新生儿医学领域，本文对PN 的适应证、应用途径、能量、液体量、营养液组成、停止时机及监测等7 个方面提出24 条推荐意见，旨在为相关从业人员提供PN 管理的建议，以改善新生儿近远期预后。直接点击即可阅读预防性人乳头瘤病毒疫苗中国临床应用指南（2025版）该指南分为人乳头瘤病毒及其流行病学，预防性HPV疫苗，一般人群HPV疫苗接种，高风险、特殊人群HPV疫苗接种，HPV疫苗的安全性，以及注意事项等6个部分，为HPV疫苗的临床应用提供了权威指导。直接点击即可阅读儿童暴发性心肌炎诊治专家建议（2025）本文主要内容包括儿童暴发型心肌炎的诊断标准、鉴别诊断、治疗措施等，以期对儿童暴发性心肌炎的诊治提供依据，提高儿童暴发性心肌炎的救治水平。直接点击即可阅读成人创伤性颅脑损伤院前与急诊诊治中国专家共识创伤性颅脑损伤(TBI)是高死亡率和高致残率的严重损伤，本共识包括TBI 院前和急诊诊治2 个部分，形成24 条推荐意见，以便指导TBI 院前和急诊相关的临床工作。直接点击即可阅读2025 AHA科学声明：血培养阴性心内膜炎与血培养阳性的心内膜炎相比，血培养阴性心内膜炎的预后更差。新的诊断工具已经改变了这种综合征的现状，并可能改善患者的预后。本文提供了血培养阴性心内膜炎的最新情况以协助一线临床医生诊断和管理血培养阴性心内膜炎。直接点击即可阅读消化心身疾病中西医结合诊疗共识意见（2024）消化心身疾病是指心理、社会、环境因素参与消化系统疾病发生、发展、转归全过程的一种心身疾病。本文参照2017 年中国中西医结合学会消化系统疾病专业委员会发布的《消化心身疾病中西医结合整体诊治专家指导意见》 ,组织有关专家进行充分讨论、补充、完善,达成共识,形成《消化心身疾病中西医结合诊疗共识意见》,以期满足临床、教学和科研的需求。直接点击即可阅读2024 JGES指南：非静脉曲张性上消化道出血的管理（第2版）出血性胃十二指肠溃疡是非静脉曲张性上消化道出血的主要原因，内镜下止血是目前非静脉曲张上消化道出血的一线治疗方法。本文主要介绍了非静脉曲张上消化道出血的评估和初始治疗，以及非静脉曲张上消化道出血的内镜止血方法的选择和内镜止血后的处理。直接点击即可阅读阿尔茨海默病疾病修饰治疗专家共识本共识对阿尔茨海默病修饰治疗的适用人群、禁忌及高风险人群、用药前的评估流程、用药方法和周期、药物有效性评估和不良反应监测等临床应用实践及相关研发进展进行了系统梳理并给出17条推荐意见，旨在为阿尔茨海默病疾病修饰治疗的临床应用提供指导。直接点击即可阅读成人患者营养不良诊断与应用指南（2025版）本文涵盖了成人患者营养不良的定义、流行病学、营养风险筛查和多层次营养评估以及诊断的全过程，并针对不同患者群体（如肥胖、危重症患者）提出个性化诊断策略，提出营养不良诊断的规范流程，最终形成27个问题、38条推荐意见，以期提升中国营养不良诊断的实践能力。直接点击即可阅读2025 中国专家共识：钠通道阻滞剂治疗局灶性癫痫（英文版）本文主要针钠通道阻滞剂（SCBs）在局灶性癫痫治疗中的使用提供共识建议。涉及局灶性癫痫患者奥卡西平、拉莫三嗪、拉考沙胺、艾司利卡西平（eslicarbazepine）、托吡酯、唑尼沙胺和苯巴那酯(cenobamate)的治疗建议，并SCB的治疗调整等9项声明达成共识。临床指南app-医问答临床指南app7.3及之后版本新增医问答板块，汇聚临床专业问答知识，扫描下方二维码进入临床指南app，按如下步骤操作，即可参与学习~点点击“阅读原文”，即可查看相关指南内容

AHA会议疫苗

2025-02-07

·医药观澜

2025年有望在中国获批上市的9款神经系统疾病新药

▎药明康德内容团队报道中枢神经系统（CNS）和精神系统疾病往往疾病机制复杂、新药研发难度大，患者存在未被满足的临床需求。本文将盘点9款有望在2025年获NMPA批准上市的CNS领域新药*，它们覆盖的适应症包括精神分裂症、阿尔茨海默病、嗜睡、失眠症等等。（*本文统计范围为于2023年1月~2025年1月期间向CDE递交上市申请的新药；新药仅统计注册分类为1类、3.1类、5.1类的新药；仅盘点有望首次获批的新药，不含新适应症）图片来源：123RF 百时美施贵宝、再鼎医药：呫诺美林曲司氯铵作用机制：M1/M4型毒蕈碱乙酰胆碱受体激动剂和毒蕈碱受体拮抗剂的组合适应症：精神分裂症 2025年1月，百时美施贵宝和再鼎医药共同申报的5.1类新药呫诺美林曲司氯铵胶囊上市申请获得CDE受理。这是一款用于治疗精神分裂症的新药KarXT，为一种口服M1/M4型毒蕈碱乙酰胆碱受体激动剂和毒蕈碱受体拮抗剂的组合。与目前主要针对多巴胺或血清素受体的抗精神病药物不同，呫诺美林优先刺激中枢神经系统中与这些疾病有关的毒蕈碱受体。2024年9月，美国FDA已经批准该产品用于治疗成人精神分裂症。再鼎医药拥有在大中华区开发、生产和商业化KarXT的权益。再鼎医药在今年的摩根大通医疗健康年会（JPM）中曾表示，KarXT有望于2025~2026年获NMPA批准上市。扬子江药业：法赞雷生作用机制：双重食欲素受体拮抗剂适应症：失眠症 2025年1月，扬子江药业全资子公司海岸药业申报的1类新药法赞雷生片上市申请获得CDE受理。公开资料显示，这是一款双重食欲素受体拮抗剂（YZJ-1139片），它能够同时抑制食欲素受体1型和2型，加快睡眠速度，延长深睡时间。扬子江药业已经完成一项YZJ-1139片治疗失眠症的3期临床试验，针对的适应症为以入睡困难/睡眠维持障碍为特征的失眠症。梯瓦：瑞玛奈珠单抗作用机制：CGRP单克隆抗体适应症：偏头痛预防性治疗 2025年1月，梯瓦（Teva）公司申报的3.1类新药瑞玛奈珠单抗注射液（fremanezumab）上市申请获得CDE受理。这是一种人源化单克隆抗体，它可选择性结合CGRP配体，并阻断两种CGRP亚型（α-和β-CGRP）与受体结合。该产品此前已在美国和欧盟获批用于成年患者偏头痛的预防性治疗。该产品有两种给药方案，可每月一次皮下注射（225mg），或每3个月一次皮下注射（675mg）。此外，其不仅可由医疗专业人员给药，亦可在家由患者或护理人员给药。翼思生物：西诺氨酯作用机制：抑制电压门控钠通道和正变构调节GABAA受体适应症：癫痫 2024年12月，SK Life Science和翼思生物共同申报的西诺氨酯片（cenobamate）上市申请获得CDE受理。西诺氨酯是翼思生物2021年从SK生物医药授权引进的CNS创新药物，它可通过抑制电压门控钠通道和正变构调节GABAA受体来减少癫痫发作甚至实现零发作。西诺氨酯片自2019~2021年在美国、欧盟和英国先后获批上市以来，已被广泛用于治疗成人癫痫患者的部分性发作。翼思生物：索安非托作用机制：双效多巴胺和去甲肾上腺素再摄取抑制剂适应症：过度嗜睡 2024年12月，翼思生物等公司共同申报的索安非托片（solriamfetol）上市申请获得CDE受理。索安非托是一种双效多巴胺和去甲肾上腺素再摄取抑制剂，该产品用于治疗与发作性睡病或阻塞性睡眠呼吸暂停综合征（OSA）相关的白天过度嗜睡。发作性睡病是一种失能性神经疾病，患者无法正常调节睡眠与苏醒的循环，导致出现嗜睡症状。索安非托可通过双重机制起到促进患者保持清醒的作用，包括引起多巴胺和去甲肾上腺素水平上升。该产品不会刺激多巴胺释放，从而减轻患者上瘾的风险。通化金马：八氢氨吖啶作用机制：乙酰胆碱酯酶抑制剂适应症：阿尔茨海默病 2024年8月，通化金马药业申报的1类新药琥珀八氢氨吖啶片的上市申请获得受理。这是通化金马开发的一款小分子乙酰胆碱酯酶抑制剂，可以同时抑制乙酰胆碱酯酶和丁酰胆碱酯酶，主要开发用于治疗轻中度阿尔茨海默病。先声药业：达利雷生作用机制：双重食欲素受体拮抗剂适应症：失眠症 2024年7月，先声药业联合申报的盐酸达利雷生片新药上市申请获得CDE受理。盐酸达利雷生片是Idorsia公司开发的抗失眠药，为一款双食欲素受体拮抗剂。先声药业拥有该产品在大中华地区开发和商业化的独家权利。与传统镇静催眠药物通过镇静大脑来促进睡眠的疗法不同，达利雷生通过阻断食欲素神经肽（食欲素A和食欲素B）与其受体的结合，降低过度活跃的中枢觉醒，帮助患者入睡和保持睡眠。由于其仅阻断食欲素受体的启动，因此可减少唤醒驱动，诱导睡眠发生，而不改变睡眠阶段的比例，且没有次日残留效应。卫材（Eisai）：莱博雷生作用机制：双重食欲素受体拮抗剂适应症：失眠症 2024年1月，卫材申报的莱博雷生片（lemborexant）上市申请获CDE受理。莱博雷生片是一款双重食欲素受体拮抗剂，此前已经在中国香港地区获批上市，用于治疗成人失眠，特别是入睡困难和/或睡眠维持困难。莱博雷生是一款小分子药物，其通过竞争性结合两种食欲素受体亚型OX1R和OX2R，抑制食欲素神经传递，调节睡眠-觉醒节律。作为一种竞争性拮抗剂，莱博雷生对OX2R具有更强的抑制作用，可抑制REM和非REM睡眠驱动，从而可以为患者提供更快的睡眠开始、更好的睡眠维持。阿斯利康（AstraZeneca）：瑞利珠单抗作用机制：长效补体C5蛋白抑制剂适应症：视神经脊髓炎谱系疾病等瑞利珠单抗（ravulizumab）是阿斯利康开发的一款长效补体C5蛋白抑制剂。它可提供即时、完全和持续的补体抑制。独特的设计使该产品具有比第一代C5补体抑制剂更长的半衰期，成人患者在初始剂量给药后，后续只需要每8周静脉注射一次。该产品已经获FDA批准治疗阵发性睡眠性血红蛋白尿症、非典型溶血性尿毒症综合征、重症肌无力、视神经脊髓炎谱系疾病等。视神经脊髓炎谱系疾病（NMOSD）是免疫介导的中枢神经系统炎性脱髓鞘疾病，以视神经炎和脊髓炎为主要临床征象，病因主要与水通道蛋白4（AQP4）抗体相关。在中国，该产品的首个上市申请已经于2023年12月获得CDE受理，第二项上市申请也已经于2024年10月获CDE受理。希望这些新药早日来到患者身边，尽快造福患者！参考资料： [1]中国国家药监局药品审评中心（CDE）官网. [2]各公司官网及公开资料本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

上市批准临床3期

2024-12-17

·PRNewswire

SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiveness in Radiopharmaceuticals

SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027, via ArtBody™, a bivalent binder platform designed to selectively target tumor cells SK Biopharmaceuticals eyes innovative small protein-based radiopharmaceuticals on safety and efficacy amid growing global demand through the joint research initiative building on the momentum for its radiopharmaceutical therapy business SEOUL, South Korea, Dec. 16, 2024 /PRNewswire/ -- SK Biopharmaceuticals, a biotech company focusing on the research, development and commercialization of treatments for disorders of the central nervous system and oncology worldwide, announced a research collaboration agreement with ProEn Therapeutics, a biotech company dedicated to advancing oncology treatments, to further extend its oncology research capability and expand its pipeline of radiopharmaceutical therapies (RPT). Under this agreement, both sides seek to advance up to two preclinical candidates for the development of novel radiopharmaceutical drugs by 2027 – the year when SK Biopharmaceuticals aims to become a global leading RPT player, via strengthened internal and external resources. This joint research builds on a series of SK Biopharmaceuticals' global strategic partnerships, including the in-licensing of a radiopharmaceutical compound, and a supply agreement to secure actinium-225, an alpha-particle emitting radioisotope, since the company unveiled its "RPT Roadmap" to gain a competitive edge in the rapidly growing field of nuclear medicine. SK Biopharmaceuticals will leverage ProEn Therapeutics' ArtBody™ platform, a dual-target binding technology that incorporates small proteins[1] to identify and target specific tumor antigens – enhancing tumor selectivity – for the development of potential cancer treatments, while minimizing damage to healthy tissues. ArtBody™, which has intrinsic advantages of high stability and structural robustness, can be mass-produced using bacteria, making it ideal for industrial applications. Il-Han Lee, Chief Executive Officer of ProEn Therapeutics, said, "We are pleased to enter this joint research, and positive that the ArtBody™ platform will generate synergy with and complement SK Biopharmaceuticals' radiopharmaceutical therapy business. ProEn Therapeutics will push to produce the best possible outcome that can meet not only the two companies' expectations, but also patients' needs." Donghoon Lee, Chief Executive Officer of SK Biopharmaceuticals, said, "This collaboration with ProEn Therapeutics is significant as the platform technology will help overcome the limitations of existing therapies. We will aim to develop more effective, safer treatments, while leading global RPT research and development efforts." About SK Biopharmaceuticals SK Biopharmaceuticals focuses on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin its expansion into oncology through research and development efforts. SK Biopharmaceuticals is the first and only Korean company to independently develop and commercialize an antiseizure medication, cenobamate (brand name: XCOPRI®), in the U.S. Cenobamate, which was commercially launched in the U.S. in 2020 by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, has successfully entered five major regions: North America, Europe, Asia, Central and South America, and the Middle East and North Africa. The company has a pipeline of eight compounds in development in both CNS disorders and oncology. For more information, visit SK Biopharmaceuticals' website at , and SK Life Science's website at . About ProEn Therapeutics ProEn Therapeutics is a biotechnology company dedicated to advancing oncology treatments through cutting-edge protein engineering. The company's innovative drug development platform, ArtBody™, focuses on bi-specific antibody-drug conjugates tailored for solid cancers. ProEn Therapeutics is also exploring next-generation therapies such as immune cell engagers and chimeric antigen receptor platforms, while extending its research in radiopharmaceuticals. The company is advancing its proprietary pipeline, while actively collaborating with partners specializing in various therapeutic modalities. For more information, visit ProEn Therapeutics' website at . SOURCE SK Biopharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准引进/卖出

100 项与 Cenobamate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11150	Cenobamate	N03A	DB06119

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
癫痫	加拿大	Endo Ventures Unlimited Co.	2023-06-12
癫痫发作	欧盟	Angelini Pharma, Inc.	2021-03-26
癫痫发作	冰岛	Angelini Pharma, Inc.	2021-03-26
癫痫发作	列支敦士登	Angelini Pharma, Inc.	2021-03-26
癫痫发作	挪威	Angelini Pharma, Inc.	2021-03-26
癫痫部分性发作	美国	SK Life Science, Inc.	2019-11-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
全身性癫痫	临床3期	日本	Ono Pharmaceutical Co., Ltd.	2022-07-12
继发性全身性癫痫发作	临床3期	美国	SK Life Science, Inc.	2022-01-14
继发性全身性癫痫发作	临床3期	澳大利亚	SK Life Science, Inc.	2022-01-14
继发性全身性癫痫发作	临床3期	德国	SK Life Science, Inc.	2022-01-14
继发性全身性癫痫发作	临床3期	匈牙利	SK Life Science, Inc.	2022-01-14
继发性全身性癫痫发作	临床3期	波兰	SK Life Science, Inc.	2022-01-14
继发性全身性癫痫发作	临床3期	西班牙	SK Life Science, Inc.	2022-01-14
HIV血清阳性	临床3期	中国	SK Life Science, Inc.	2021-03-08
HIV血清阳性	临床3期	日本	SK Life Science, Inc.	2021-03-08
HIV血清阳性	临床3期	韩国	SK Life Science, Inc.	2021-03-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04690751 (CTgov)	临床1期	癫痫部分性发作	28	Cenobamate 200Mg Tab Fasted (Treatment A)	積網艱壓鹽蓋憲簾範顧(遞襯遞鏇糧蓋窪觸醖範) = 艱夢餘艱鏇廠蓋夢遞窪醖鹽獵鑰齋鏇鏇範糧觸 (鑰艱蓋壓醖齋窪築簾淵, 願齋築鏇衊蓋壓膚範淵 ~ 餘鑰餘製簾鹽顧窪襯齋) 更多	-	2024-08-12
				Cenobomate Oral Suspension Fasted (Treatment B)	積網艱壓鹽蓋憲簾範顧(遞襯遞鏇糧蓋窪觸醖範) = 鹽夢鹹遞選觸簾糧廠餘醖鹽獵鑰齋鏇鏇範糧觸 (鑰艱蓋壓醖齋窪築簾淵, 衊夢餘鬱艱鏇糧廠齋獵 ~ 鑰繭簾憲鹽網餘醖窪餘) 更多
NCT03678753 (Pubmed \| Cochrane Database Syst Rev)	临床3期	耐药性癫痫追加	659	Cenobamate add-on therapy	餘範築願網齋餘窪壓獵(廠鹹窪餘遞鹹簾膚網襯) = 範衊襯艱鹹製鹽範艱衊鬱製繭壓積淵窪衊襯獵 (衊選憲醖網積鬱廠膚齋, 1.02 ~ 1.27) 更多	积极	2024-08-01
				Placebo	餘範築願網齋餘窪壓獵(廠鹹窪餘遞鹹簾膚網襯) = 鹽鑰觸憲糧構顧膚願鹽鬱製繭壓積淵窪衊襯獵 (衊選憲醖網積鬱廠膚齋, 1.02 ~ 1.27) 更多
EAN2024	N/A	癫痫	16	Cenobamate	選範繭齋襯繭鏇醖餘淵(餘廠遞糧醖選鏇衊築獵) = 夢築選鏇鑰糧觸鏇餘繭遞積憲觸壓襯齋築憲願 (範鹹築觸憲壓繭簾廠觸 ) 更多	积极	2024-06-28
EAN2024	N/A	癫痫发作	-	Cenobamate	築廠壓夢窪顧憲壓壓鏇(範觸積醖鑰夢膚範蓋餘) = 鏇構蓋憲積範醖鬱憲願獵襯壓鹹網壓網鬱簾淵 (鹹鹽醖壓鑰糧製窪範繭 ) 更多	-	2024-06-28
P1-1.001 (AAN2024)	N/A	Lennox-Gastaut综合征	76	Cenobamate	構鑰糧襯鑰獵憲築廠鏇(膚窪鬱觸壓餘範壓憲鏇) = 積醖選網觸餘壓積築顧膚顧憲廠鬱夢糧壓醖鏇 (鏇糧壓鹹壓壓選餘積鹹 ) 更多	积极	2024-04-09
				Previous antiseizure medications (ASMs)	構鑰糧襯鑰獵憲築廠鏇(膚窪鬱觸壓餘範壓憲鏇) = 網憲積艱窪糧範網網窪膚顧憲廠鬱夢糧壓醖鏇 (鏇糧壓鹹壓壓選餘積鹹 ) 更多
P2-1.003 (AAN2024)	N/A	癫痫发作	176	Cenobamate	憲齋衊鹽獵築觸壓構築(繭膚製範選餘鹹築廠構) = 餘積衊餘鏇鹹醖繭窪艱餘襯鹹蓋積壓鏇顧繭衊 (觸顧構構膚夢衊夢糧壓 ) 更多	积极	2024-04-09
				Previous antiseizure medications (ASMs)	憲齋衊鹽獵築觸壓構築(繭膚製範選餘鹹築廠構) = 範選鏇襯願鬱鬱築築積餘襯鹹蓋積壓鏇顧繭衊 (觸顧構構膚夢衊夢糧壓 ) 更多
P8-1.004 (AAN2024)	N/A	术后疼痛	7,835	Cenobamate	製鬱願淵鬱衊顧齋淵淵(蓋鑰選齋積壓餘齋製夢) = 蓋觸積觸襯糧淵膚範鏇鏇鏇鏇齋構襯鹽窪鏇簾 (範廠繭鏇願淵憲壓淵觸 ) 更多	积极	2024-04-09
AAN2024	N/A	-	-	Cenobamate monotherapy	鹹網淵壓製簾網衊醖憲(衊餘餘繭鹽鏇範鹽築鏇) = 鏇構構構膚衊網膚選餘製網夢積鏇衊齋夢繭築 (製窪齋醖窪繭鹽醖艱艱 ) 更多	-	2024-04-09
S29.003 (AAN2024)	N/A	癫痫发作	-	Cenobamate	膚醖壓糧淵獵廠艱觸艱(鏇淵簾顧齋獵遞糧選簾) = 蓋醖鑰餘鏇憲鏇遞鏇簾顧範醖衊廠膚鬱鹹網顧 (鏇餘築網醖積餘範積糧 ) 更多	积极	2024-04-09
NCT02535091 (Phase III, Multicenter, Open-Label Study, Pubmed \| Drugs Aging)	临床3期	癫痫发作	1,340	Cenobamate	糧顧夢憲衊衊鹹鑰糧網(襯餘襯齋願膚鏇窪廠選) = somnolence and dizziness in overall patients, and somnolence, dizziness, fall, fatigue, balance disorder, and upper respiratory tract infection in older patients 遞糧獵願積衊鹽衊醖顧 (鏇鏇獵簾襯糧廠餘構鏇 ) 更多	积极	2024-03-01
				Placebo